



Provided by the author(s) and University of Galway in accordance with publisher policies. Please cite the published version when available.

Title	Platelet-rich emboli are associated with von Willebrand factor levels and have poorer revascularization outcomes
Author(s)	Douglas, Andrew; Fitzgerald, Seán; Mereuta, Oana Madalina; Rossi, Rosanna; O'Leary, Sean; Pandit, Abhay; McCarthy, Ray; Gilvarry, Michael; Holmegaard, Lukas; Abrahamsson, Margareta; Jerndal, Mikael; Dehlfors, Niclas; Brennan, Paul; Power, Sarah; O'Hare, Alan; Griffin, Emma; Kallmes, David F.; Brinjikji, Waleed; Szikora, István; Tatlisumak, Turgut; Rentzos, Alexandros; Thornton, John; Doyle, Karen M.
Publication Date	2019-11-04
Publication Information	Douglas, Andrew, Fitzgerald, Seán, Mereuta, Oana Madalina, Rossi, Rosanna, Leary, Sean, Pandit, Abhay, McCarthy, Ray, Gilvarry, Michael, Holmegaard, Lukas, Abrahamsson, Margareta, Jerndal, Mikael, Dehlfors, Niclas, Brennan, Paul, Power, Sarah, Hare, Alan, Griffin, Emma, Kallmes, David F., Brinjikji, Waleed, Szikora, István, Tatlisumak, Turgut, Rentzos, Alexandros, Thornton, John, Doyle, Karen. (2019). Platelet-rich emboli are associated with von Willebrand factor levels and have poorer revascularization outcomes. <i>Journal of NeuroInterventional Surgery</i> . doi: 10.1136/neurintsurg-2019-015410
Publisher	BMJ Publishing Group
Link to publisher's version	<a href="https://dx.doi.org/10.1136/neurintsurg-2019-015410">https://dx.doi.org/10.1136/neurintsurg-2019-015410</a>
Item record	<a href="http://hdl.handle.net/10379/15611">http://hdl.handle.net/10379/15611</a>
DOI	<a href="http://dx.doi.org/10.1136/neurintsurg-2019-015410">http://dx.doi.org/10.1136/neurintsurg-2019-015410</a>

Some rights reserved. For more information, please see the item record link above.



**Manuscript Title:** Platelet-rich emboli are associated with von Willebrand Factor levels and have poorer Revascularization Outcomes

**Authors:** Andrew Douglas<sup>1</sup>, Seán Fitzgerald\*<sup>1,2</sup>, Oana Madalina Mereuta<sup>1,2</sup>, Rosanna Rossi<sup>1</sup>, Seán O’Leary<sup>1</sup>, Abhay Pandit<sup>1</sup>, Ray McCarthy<sup>3</sup>, Michael Gilvarry<sup>3</sup>, Lukas Holmegaard<sup>4</sup>, Margareta Abrahamsson<sup>4</sup>, Mikael Jerndal<sup>4</sup>, Niclas Dehlfors<sup>4</sup>, Paul Brennan<sup>5</sup>, Sarah Power<sup>5</sup>, Alan O’Hare<sup>5</sup>, Emma Griffin<sup>5</sup>, David F. Kallmes<sup>2</sup>, Waleed Brinjikji<sup>2,6</sup>, Istvan Szikora<sup>7</sup>, Turgut Tatlisumak<sup>8</sup>, Alexandros Rentzos<sup>4</sup>, John Thornton<sup>5,9</sup>, Karen M. Doyle<sup>1,10</sup>.

<sup>1</sup>CÚRAM–Centre for Research in Medical Devices, National University of Ireland Galway, Galway, Ireland, <sup>2</sup>Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA, <sup>3</sup>Cerenovus, Galway Neuro Technology Centre, Galway, Ireland, Department of Radiology, Sahlgrenska University Hospital, Göteborg, Sweden, <sup>5</sup>Department of Radiology, Beaumont Hospital Dublin, Dublin, Ireland, <sup>6</sup>Department of Neurosurgery, Mayo Clinic, Rochester, Minnesota, USA, <sup>7</sup>Department of Neurointerventions, National Institute of Neurosciences, Budapest, Hungary, <sup>8</sup>Department of Clinical Neuroscience, Institute of Neuroscience and Physiology, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, <sup>9</sup>Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland, <sup>10</sup>Department of Physiology and Galway Neuroscience Centre, National University of Ireland Galway, Galway, Ireland.

\*These Authors contributed equally to this work.

**Word Count:** 3,093 Words, **Word count in abstract:** 240

**Number of Tables/Figures/References:** Tables = 2, Figures = 2, References = 33

**Corresponding Author:** Dr. Karen Doyle

**Address:** CÚRAM–Centre for Research in Medical Devices, National University of Ireland Galway, Galway, Ireland

**Email:** Karen.doyle@nuigalway.ie

**Telephone:** +353-(0)91-49366

## **Abstract**

**Background and Aims:** Platelets and von Willebrand factor are key factors in thrombosis and thus are likely key components of acute ischemic stroke emboli. We aimed to characterize platelet and von Willebrand factor levels in acute ischemic stroke emboli and assess associations between their expression levels and clinical and procedural information.

**Materials and Method:** Histopathological and immunohistochemical analysis of emboli collected as part of the multi-institutional RESTORE registry was performed. The composition of the emboli was quantified using Orbit Image Analysis ([www.Orbit.bio](http://www.Orbit.bio)) machine learning software. Correlations between clot components and clinical and procedural information were assessed using the Chi-Squared test.

**Results:** Ninety-one emboli samples retrieved from sixty-three patients were analyzed in the study. The mean platelet (CD42b) content of the clots was 33.9% and the mean von Willebrand factor content of the clots was 29.8%. There was a positive correlation between platelet and von Willebrand factor levels ( $\rho=0.564$ ,  $p<0.001^*$ ,  $n=91$ ). There was an inverse correlation between both platelets and vWF levels and percentage of red blood cells in the emboli (CD42b vs RBC:  $\rho=-0.535$ ,  $p<0.001^*$ ,  $n=91$ ; vWF vs RBC:  $\rho=-0.366$ ,  $p<0.001^*$ ,  $n=91$ ). Eighty-one percent of patients in the low platelet group had a good revascularization outcome (TICI 2c/3) compared to 58% in the high-platelet group ( $X^2=5.856$ ,  $p=0.016$ ).

**Conclusion:** Platelet and vWF levels in AIS emboli correlate with each other and both have an inverse relationship with red blood cell composition. Patients with platelet-rich clots have poorer revascularization outcomes.

## INTRODUCTION

There is a growing consensus within the field of acute ischemic stroke treatment that the histological structure and composition of the occlusive emboli significantly influences the outcome for patients treated with both rtPA and mechanical thrombectomy devices [1-5]. Platelets and von Willebrand factor are key factors in thrombus formation and have previously been shown to be key components of acute ischemic stroke thromboemboli [6, 7].

Platelets are anucleated cell fragments that are produced in large numbers by megakaryocytes found mainly in bone marrow [8]. Platelets circulate in the blood for 7 to 10 days and help to maintain homeostasis in healthy non-atherosclerotic vessels. Platelets play a key role mediating primary hemostasis after endothelial injury [9]. Upon vessel wall injury platelets adhere to exposed collagen by means of their collagen receptors GPVI and integrin  $\alpha_2\beta_1$ , initiating intracellular signaling, platelet activation and thrombus formation [10]. Under high shear conditions such as in small arteries or stenosis due to atherosclerosis, platelet adhesion becomes more dependent on the interaction between the platelet GPIb receptor and vWF [11].

von Willebrand factor (vWF) is a large multimeric plasma protein synthesized in megakaryocytes and endothelial cells [12]. A significant body of research has implicated von Willebrand Factor as both a key player in thrombus formation and also as a risk factor for acute ischemic stroke [13-17]. Elevated serum levels of vWF has been shown to predict increased inpatient complications, neurological worsening and reduced functional outcomes when compared to normal levels [18].

## **MATERIALS AND METHODS**

### ***Study Design***

This General Data Protection Regulation compliant study was approved by the National University of Ireland Galway research ethics committee and the respective institutional research ethics committee at Beaumont Hospital, Dublin, Ireland and Sahlgrenska University Hospital, Gothenburg, Sweden. The inclusion criteria were as follows; Patients >18 years, having undergone mechanical thrombectomy treatment for acute ischemic stroke and with embolic material available for analysis. All patients were examined neurologically upon arrival and NIHSS was recorded. Stroke severity on admission was dichotomized using NIHSS scores as mild to moderate (NIHSS <16) and severe (NIHSS ≥16).

### ***Per-pass Clot Collection and Processing***

Clots were collected in a per-pass manner, meaning that where multiple procedural passes were used to treat the patients, clot fragments from each pass were collected separately. On retrieval from the patient, each clot was immediately fixed in 10% phosphate-buffered formalin. Clots were shipped to the Department of Physiology in the National University of Ireland Galway and upon arrival, each case and clot fragment was logged in the RESTORE registry. Gross photographs were taken of each clot fragment and all clots were then processed using a standard tissue processing protocol and embedded in paraffin-wax. The formalin-fixed paraffin-embedded clot material was cut into 3µm sections for histology and immunohistochemical staining.

## **Martius Scarlet Blue Staining**

Two representative sections were stained with Martius Scarlett Blue (MSB) to identify the standard clot components (red blood cells, white blood cells, fibrin, platelets/other). Briefly, slides were deparaffinized in xylene and rehydrated through alcohol to water. Slides were then placed into Bouin's fluid at 56°C in a water bath for 1 hour, then rinsed in running tap water (5 mins). Slides were then placed into filtered Iron ammonium-celestine blue solution (10 mins), rinsed in running tap water (5 mins), stained with filtered Mayer's Hematoxylin (10 mins) and rinsed in warm running water to blue. Slides were rinsed with 95% alcohol (1 min) followed by fresh Martius yellow (5 mins), rinsed in distilled water (1 min) and then stained in filtered Crystal scarlet (10 mins). Slides were then differentiated in fresh with phosphotungstic acid (7 mins), stained with Methyl blue (10 mins) and rinsed in 1% aqueous acetic (1 min). Sections were dehydrated in absolute alcohol (2 fast dips), cleared in xylene and mounted in DPX.

## **Immunohistochemistry**

Immunohistochemical staining for platelets (CD42b) and vWF was performed using a Ventana Discovery autostainer using a discovery RedMap kit (Roche 760-123). Antigen retrieval with Tris-EDTA was performed for platelet staining (anti-CD42b); no antigen retrieval was used for vWF staining. Primary antibody (anti-CD42b; Abcam ab27669, 1:200 dilution, anti-vWF; Dako A-0082, 1:200 dilution) incubation time was 30mins, this was followed by a 30min incubation with a universal secondary antibody (Roche 760-4205). Counterstaining of tissue was using hematoxylin was performed for 6 mins followed by a 2min incubation in bluing reagent. Sections were then washed in warm soapy water to remove oil based liquid cover-slip, followed by rinsing in distilled water. Sections were then dehydrated in alcohol, cleared in

xylene and mounted with DPX. Negative controls were performed by omission of the primary antibody step.

### **Slide scanning and Quantification**

Histology and immunohistochemically stained slides were scanned on an Olympus VS120 slide scanner at 20x magnification and digital whole-slide scan images were generated. Histologic and immunohistochemical quantification was performed on the digital slides using Orbit Image Analysis Software ([www.orbit.bio](http://www.orbit.bio)) as described previously [19]. Percentage area of each component (RBC, WBC, Fibrin and Platelet/other) within the clot was calculated for the histological staining with MSB. Percentage area of positive IHC staining was calculated separately for CD42b and vWF.

### ***Statistical analysis***

All statistical correlations were assessed using IBM SPSS Statistics 22. Platelet-rich clots were defined as CD42b  $\geq$  mean, vWF-rich clots were defined as vWF  $\geq$  mean etc. Spearman correlations were used to assess associations between continuous variables. Correlations between categorical variables were assessed using the Chi-Squared test. GraphPad Prism 8 was used to generate graphs and figures. Results are reported as mean ( $\pm$ SD) or number and % of cases. A level of statistical significance for all analyses was set at  $p < 0.05$ .



## RESULTS

### *Patient Cohort*

Sixty-three patients were included in the study. Table 1 shows the clinical demographics of the patient cohort. Forty-four percent of patients were treated with rt-PA. The suspected etiology was Large Artery (14.3%), Cardioembolic (31.7%), Cryptogenic (50.8%) and Other (3.2%). Aspiration alone (64%) was the most commonly used endovascular treatment strategy, with Stentriever devices being deployed in the remaining 36 % of patients. TICI 2c/3 was achieved in 71% of patients treated, with a mean number of passes of 2.4. Fifty-one percent of patients had a severe stroke defined as an NIHSS score of  $\geq 16$ . The average reported clot length was 15.1mm. The majority of cases had an internal carotid artery (ICA) or middle cerebral artery (MCA) occlusion (29% and 68%, respectively) and 18 cases (29%) had occlusions that spanned two or more locations.

**Table 1.** Clinical details of patient cohort.

		Number of Patients ( <i>n</i> =63)	(%)
<b>Site:</b>			
ICA		18	28.6%
M1		43	68.3%
M2		13	20.6%
A1, A2, A3		3	4.8%
Basilar		1	1.6%
P1		1	1.6%
<b>rt-PA:</b>			
Yes		28	44.4%
No		35	55.6%
<b>Suspected Etiology:</b>			
Large Artery		9	14.3%
Cardioembolic		20	31.7%
Unknown		32	50.8%
Other		2	3.2%
<b>No of Passes Required:</b>			
Mean	2.4 ± 2.8		
1		34	54.0%
2		9	14.3%
3		6	9.5%
4		5	7.9%
5+		9	14.3%
<b>Final TICI Score:</b>			
1		1	1.6%
2a		3	4.8%
2b		8	12.7%
2c		16	25.4%
3		35	55.5%
<b>NIHSS Stroke Severity:</b>			
Mild to Moderate (NIHSS<16)		30	47.6%
Severe (NIHSS≥16)		32	50.8%
Not Available		1	1.6%
<b>Thrombectomy Technique:</b>			
Aspiration Only		40	63.5%
Stentriever Used		23	36.5%

ICA: Internal Carotid Artery; M1 and M2 segment of the Middle Cerebral Artery; A1, A2, A3: Anterior Cerebral Artery segments; P1: Posterior Cerebral Artery P1 segment; rtPA: tissue-plasminogen activator; TICI Score: Thrombolysis in Cerebral Infarction (TICI) Score.  
 \*The total percentage of sites is not equal to 100 because some patients have multiple sites of occlusion.

### ***Histological Composition***

The MSB stain was used to assess the histological composition of the emboli (Table 2). Red blood cells were the dominant components of AIS clots with their mean compositions being 39.2%, followed by fibrin (30.7%) and platelets/other (27.7%). The average white blood cell composition was 2.4%. No significant difference in thrombus composition was observed between thrombi that were removed in one pass (54.0%) versus thrombi that required multiple passes (46.0%).

**Table 2.** Histological, Immunohistochemical and Spearman's rho Results.

		Histology - MSB Staining				Immunohistochemistry		
		Red blood cells	White blood cells	Fibrin	Platelets / Other	CD42b	vWF	
<b>Quantification</b>	<b>Average:</b>	39.20%	2.40%	30.70%	27.70%	33.90%	29.80%	
	<b>Minimum:</b>	0.40%	0.10%	2.90%	1.40%	0.50%	0.10%	
	<b>Maximum:</b>	90.80%	7.60%	71.20%	89.20%	93.20%	94.30%	
<b>Spearman's Rho Correlations</b>								
		Red Blood Cells	White Blood Cells	Fibrin	Platelets / Other	CD42b	vWF	
<b>Spearman's rho</b>	<b>Red Blood Cells</b>	Correlation Coefficient Sig. (2-tailed) N	1.000  91	-.235* 0.025 91	-.345** 0.001 91	-.728** < 0.001 91	-.535** < 0.001 91	-.366** < 0.001 91
	<b>White Blood Cells</b>	Correlation Coefficient Sig. (2-tailed) N	-.235* 0.025 91	1.000  91	.306** 0.003 91	0.098 0.356 91	.353** 0.001 91	-0.018 0.864 91
	<b>Fibrin</b>	Correlation Coefficient Sig. (2-tailed) N	-.345** 0.001 91	.306** 0.003 91	1.000  91	-.237* 0.024 91	0.031 0.769 91	-0.077 0.467 91
	<b>Platelets and Other</b>	Correlation Coefficient Sig. (2-tailed) N	-.728** < 0.001 91	0.098 0.356 91	-.237* 0.024 91	1.000  91	.534** < 0.001 91	.444** < 0.001 91
	<b>CD42b</b>	Correlation Coefficient Sig. (2-tailed) N	-.535** < 0.001 91	.353** 0.001 91	0.031 0.769 91	-.237* 0.024 91	1.000 < 0.001 91	.564** < 0.001 91
	<b>vWF</b>	Correlation Coefficient Sig. (2-tailed) N	-.366** < 0.001 91	-0.018 0.864 91	-0.077 0.467 91	.444** < 0.001 91	.564** < 0.001 91	1.000  91

\*Correlation is significant at the 0.05 level (2-tailed). \*\*Correlation is significant at the 0.01 level (2-tailed).

### ***Platelet composition correlates with vWF levels***

The composition of platelets (CD42b) varied from 0.5% to 93.2% of the total area, with a mean value of 33.9%. There was a positive correlation between platelets quantified using the specific anti-CD42b antibody and platelets/other quantified using the MSB stain ( $\rho=0.534$ ,  $p<0.001^*$ ,  $n=91$ ), an example can be seen in Figure 1. The composition of vWF varied from 0.1% to 94.3% of the total area, with a mean value of 29.8%. There was a positive correlation between platelet (CD42b) levels and vWF levels ( $\rho=0.564$ ,  $p<0.001^*$ ,  $n=91$ ), as can be seen in Figure 2.

### ***Inverse correlation between red blood cells and both platelets and vWF***

There was an inverse correlation between the percentage of platelets (CD42b) and red blood cell composition ( $\rho=-0.535$ ,  $p<0.001^*$ ,  $n=91$ ) as can be seen in Table 2. There was also an inverse correlation between the percentage of vWF and red blood cell composition ( $\rho=-0.366$ ,  $p<0.001^*$ ,  $n=91$ ).

### ***Platelets correlate with white blood cells***

A positive correlation between the percentage of platelets (CD42b) and white blood cell composition was observed ( $\rho=0.353$ ,  $p<0.001^*$ ,  $n=91$ ), as can be seen in Table 2. No significant correlations were observed between the level of platelets (CD42b) and fibrin. Similarly, no significant correlations were noted between the level of vWF and fibrin or white blood cells measured using the MSB stain.

### ***Platelet-Rich Clots are associated with a poorer TICI Score***

Eighty-one percent of patients in the low platelet group (CD42b < Mean) had a good revascularization outcome (TICI 2c/3) compared to 58% in the high-platelet (CD42b > Mean) group ( $X^2=5.856$ ,  $p=0.016$ ). Similarly, 59% of patients in the low platelet cohort had complete revascularization (TICI 3) compared to just 37% in the in the high-platelet cohort ( $X^2=4.15$ ,  $p=0.042$ ). von Willebrand factor levels did not have a significant influence on revascularization outcome. The mechanical thrombectomy technique used (Aspiration Only vs Stentriever) also did not have a significant influence on final revascularization outcome in any subset of patients.

### ***Clot composition is not associated with Stroke Severity***

The histopathological composition of the clot did not affect stroke severity. None of the clot components quantified including red blood cells, white blood cells, fibrin, platelets and vWF showed a significant association with stroke severity measured using the NIHSS score (Mild to Moderate < 16; Severe  $\geq 16$  ).

## DISCUSSION

In this study we demonstrate that platelet-rich clots are associated with poorer revascularization outcomes when mechanical thrombectomy is performed. Additionally we demonstrated that platelet-rich clots are associated with von Willebrand Factor levels, reduced red blood cell-content and increased white blood cell-content. These findings are important as they could help to individualize treatment strategy based on clot composition and ultimately improve patient outcome.

In a previous study we demonstrated that platelet-rich clots, as identified using the MSB stain, are isodense on NCCT [20]. In that study, we quantified red blood cells, white blood cells, Fibrin and Platelets/Other. We specifically referred to the latter category as Platelets/Other as we were conscious that the MSB histological stain could not demarcate platelets from other key components of thrombus formation such as von Willebrand Factor and Fibrinogen. In this study we use immunohistochemical staining with specific antibodies for both Platelets (CD42b) and von Willebrand factor to quantify the expression levels of each component. We demonstrate that there is a significant positive correlation between platelets/other measured using the MSB stain and platelet levels measured using the platelet specific anti-CD42b antibody. This finding validates the approach of our previous study and confirms that the MSB stain is a more comprehensive histological stain than the traditional Hematoxylin and Eosin stain for acute ischemic stroke clot characterization.

Rapid binding of vWF to exposed collagen types I and III after endothelial injury initiates a conformational change in vWF resulting in binding sites for platelet GPIb becoming available [10]. The reversible nature of the GPIb-vWF interaction allows for slowing of platelets thus allowing GPVI and integrin  $\alpha_2\beta_1$  to bind to collagen and arrest movement.

Subsequent intracellular signaling leads to the synthesis and release of secondary platelet agonists such as thromboxane A<sub>2</sub>, thrombin and adenosine diphosphate (ADP). These agonists cause platelet surface integrin's such as GpIIb/IIIa to shift to a high affinity state [21]. Platelet aggregation follows by means of the activated platelet GpIIb/IIIa binding to its primary ligand fibrinogen and also vWF leading to platelet-platelet crosslinking. We demonstrate that Platelets and vWF account for a considerable proportion of emboli composition with mean values of 33.9% & 29.8%, respectively. Additionally we show that there is a significant positive correlation between Platelets and vWF levels in acute ischemic stroke emboli. It has been suggested the red blood cell rich-clots form as a result of stasis in a vessel, but clots that form under high shear conditions are rich in platelets and vWF [11].

The results of our study also demonstrate that there was a significant inverse correlation between both platelets (CD42b), von Willebrand factor levels and red blood cell composition. These results are in agreement with a recent study on the structural analysis of acute ischemic stroke that found that red blood cell-rich clots are composed mainly of densely packed red blood cells supported by a thin fibrin network, whilst platelet-rich clots contain dense fibrin structures aligned with vWF and packed with platelets [22]. We demonstrate that platelet-rich clots correlated with a poor revascularization outcome and previous studies have also shown that fibrin/platelets rich clots are more difficult to retrieve than red blood cell-rich clots [23]. Contracting (activated) platelets have been shown to actively remodel the fibrin network of thrombi leading to an increase in fibrin density and a consequential decrease in clot volume and increase in clot stiffness [24]. This platelet-induced contraction of the fibrin network may help to explain the poorer revascularization outcome in these patients. Further investigation is warranted to understand the initial molecular response to ischemic stroke and how each clot component influences the structural and



mechanical properties of the clot and their interaction with mechanical thrombectomy devices [25].

It has been suggested that targeting vWF with novel pharmacological agents could help to overcome some of the limitations of current thrombolytic drugs and also in secondary stroke prevention [6, 26]. It is clear that vWF is a key mediator of thrombus formation and thus is a key component of thromboemboli. However, no significant association was found between stroke severity and vWF composition within the clot. Additionally none of the other clot components quantified, including platelets, has a significant relationship with stroke severity. This suggests that clot composition is not a key determinant of stroke severity and that occlusion location remains the key determinant of stroke severity [27].

Recent evidence suggests that the immune system can have a significant effect on blood coagulation and thrombus formation [28]. Atherosclerosis is an inflammatory process resulting in the deposition of cholesterol-rich plaques and under inflammatory conditions the crosstalk between platelets, the coagulation cascade and the endothelium is no longer able to maintain homeostasis. Platelets and white blood cells appear to have a reciprocal relationship in terms of thrombosis. Activated platelets release cytokines that can modulate white blood cells activation resulting in the formation of white blood cells-platelet aggregates that serve to localize activated white blood cells to the site of the arterial thrombus [29, 30]. Conversely, activated white blood cells mediate a rapid response to pro-coagulant stimuli by inducing platelet activation and aggregation through the release of platelet activators [31-33]. In the current study we demonstrate that there is a significant positive correlation between platelets (CD42b) and white blood cell levels suggesting that there is a relationship between these two components.

Our study has limitations. Firstly, only clots from patients that had a successful mechanical thrombectomy procedure could be studied. Clots that were not recovered or that dissolved after rt-PA treatment could not be studied. Second, TICI scores were reported at each site and not measured using a central core lab which may have resulted in some site-to-site variability.

## **CONCLUSIONS**

Patients with platelet-rich clots have poorer revascularization outcome. Platelet and vWF levels in AIS emboli correlate with each other and both have an inverse relationship with red blood cell composition. There is a significant positive correlation between platelet (CD42b) and white blood cell levels suggesting a possible inflammatory mechanism in platelet-rich cases.

## **ACKNOWLEDGEMENTS**

The authors would like to gratefully acknowledge the invaluable contributions made by the Interventional, Nursing and Clinical coordination teams at each of the sites included in the Restore registry. The authors also wish to thank Catherine Curran and our Industrial Partners Cerenovus.

## **FUNDING STATEMENT**

This work was supported by the European Regional Development Fund and Science Foundation Ireland grant number (13/RC/2073).

## **COMPETING INTERESTS STATEMENT**

The authors declare no competing interests (Funding, Employment or Personal financial interests) in relation to the work described herein.

## **CONTRIBUTORSHIP STATEMENT**

Andrew Douglas, Seán Fitzgerald, and Karen M. Doyle were all involved in all stages of the manuscript from concept design to drafting the manuscript. Lukas Holmegaard, Margareta Abrahamsson, Mikael Jerndal, Niclas Dehlfors, Paul Brennan, Sarah Power, Alan O'Hare, Emma Griffin, Istvan Szikora, Turgut Tatlisumak, Alexandros Rentzos and John Thornton were responsible for collecting and recording the clinical and procedural information from patients. All authors reviewed, edited and approved the final manuscript prior to submission.

## **DATA SHARING STATEMENT**

De-identified participant data and corresponding histological data will be made available upon reasonable request.

## References

1. Dobrocky T, Piechowiak E, Cianfoni A, et al. Thrombectomy of calcified emboli in stroke. Does histology of thrombi influence the effectiveness of thrombectomy? *Journal of neurointerventional surgery*. 2018;10(4):345-50.
2. Gunning GM, McArdle K, Mirza M, et al. Clot friction variation with fibrin content; implications for resistance to thrombectomy. *Journal of NeuroInterventional Surgery*. 2017.
3. Ducroux C, Di Meglio L, Loyau S, et al. Thrombus neutrophil extracellular traps content impair tPA-induced thrombolysis in acute ischemic stroke. *Stroke*. 2018;49(3):754-7.
4. Saver JL, Goyal M, Bonafe A, et al. Stent-Retriever Thrombectomy after Intravenous t-PA vs. t-PA Alone in Stroke. *New England Journal of Medicine*. 2015;372(24):2285-95.
5. Funatsu N, Hayakawa M, Hashimoto T, et al. Vascular wall components in thrombi obtained by acute stroke thrombectomy: clinical significance and related factors. *Journal of neurointerventional surgery*. 2019;11(3):232-6.
6. Denorme F, Langhauser F, Desender L, et al. ADAMTS13-mediated thrombolysis of t-PA resistant occlusions in ischemic stroke in mice. *Blood*. 2016.
7. Niesten JM, van der Schaaf IC, van Dam L, et al. Histopathologic composition of cerebral thrombi of acute stroke patients is correlated with stroke subtype and thrombus attenuation. *PLoS ONE*. 2014;9(2):e88882.
8. Patel SR, Hartwig JH, Italiano JE. The biogenesis of platelets from megakaryocyte proplatelets. *The Journal of clinical investigation*. 2005;115(12):3348-54.
9. Nurden AT, Nurden P, Sanchez M, et al. Platelets and wound healing. *Frontiers in bioscience: a journal and virtual library*. 2008;13:3532-48.
10. Denorme F, De Meyer SF. The VWF-GPIb axis in ischaemic stroke: lessons from animal models. *Thrombosis and haemostasis*. 2016;116(10):597-604.
11. Ruggeri ZM, Orje JN, Habermann R, et al. Activation-independent platelet adhesion and aggregation under elevated shear stress. *Blood*. 2006;108(6):1903-10.
12. De Meyer SF, Deckmyn H, Vanhoorelbeke K. von Willebrand factor to the rescue. *Blood*. 2009;113(21):5049-57.
13. Bongers TN, de Maat MP, van Goor M-LP, et al. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability. *Stroke*. 2006;37(11):2672-7.
14. Van Schie M, De Maat M, Dippel D, et al. von Willebrand factor propeptide and the occurrence of a first ischemic stroke. *Journal of Thrombosis and Haemostasis*. 2010;8(6):1424-6.
15. Zhao B-Q, Chauhan AK, Canault M, et al. von Willebrand factor–cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. *Blood*. 2009;114(15):3329-34.
16. Sanders YV, Eikenboom J, de Wee EM, et al. Reduced prevalence of arterial thrombosis in von Willebrand disease. *Journal of Thrombosis and Haemostasis*. 2013;11(5):845-54.
17. Tzoulaki I, Murray GD, Lee AJ, et al. Relative value of inflammatory, hemostatic, and rheological factors for incident myocardial infarction and stroke: the Edinburgh Artery Study. *Circulation*. 2007;115(16):2119-27.
18. Samai A, Monlezun D, Shaban A, et al. Von Willebrand factor drives the association between elevated factor VIII and poor outcomes in patients with ischemic stroke. *Stroke*. 2014;45(9):2789-91.
19. Fitzgerald S, Wang S, Dai D, et al. Machine-Learned Characterization of Acute Ischemic Stroke Clots Reveals a Correlation Between Clot Composition and HU Density on CT. 2018.
20. Fitzgerald ST, Wang S, Dai D, et al. Platelet-rich clots as identified by Martius Scarlet Blue staining are isodense on NCCT. *Journal of neurointerventional surgery*. 2019:neurintsurg-2018-014637.
21. Offermanns S. Activation of platelet function through G protein–coupled receptors. *Circulation research*. 2006;99(12):1293-304.

22. Staessens S, Denorme F, Francois O, et al. Structural analysis of ischemic stroke thrombi: histological indications for therapy resistance. *Haematologica*. 2019.
23. Maekawa K, Shibata M, Nakajima H, et al. Erythrocyte-Rich Thrombus Is Associated with Reduced Number of Maneuvers and Procedure Time in Patients with Acute Ischemic Stroke Undergoing Mechanical Thrombectomy. *Cerebrovascular diseases extra*. 2018;8(1):39-49.
24. Kim OV, Litvinov RI, Alber MS, et al. Quantitative structural mechanobiology of platelet-driven blood clot contraction. *Nat Commun*. 2017;8(1):1274-.
25. Fraser JF, Collier LA, Gorman AA, et al. The Blood and Clot Thrombectomy Registry and Collaboration (BACTRAC) protocol: novel method for evaluating human stroke. *Journal of neurointerventional surgery*. 2019;11(3):265-70.
26. Buchtele N, Schwameis M, Gilbert JC, et al. Targeting von Willebrand factor in ischaemic stroke: focus on clinical evidence. *Thrombosis and haemostasis*. 2018;118(06):959-78.
27. Fischer U, Arnold M, Nedeltchev K, et al. NIHSS score and arteriographic findings in acute ischemic stroke. *Stroke*. 2005;36(10):2121-5.
28. Swystun LL, Liaw PC. The role of leukocytes in thrombosis. *Blood*. 2016;128(6):753.
29. Clark SR, Ma AC, Tavener SA, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. *Nature medicine*. 2007;13(4):463.
30. Lindemann S, Tolley ND, Dixon DA, et al. Activated platelets mediate inflammatory signaling by regulated interleukin 1 $\beta$  synthesis. *The Journal of cell biology*. 2001;154(3):485-90.
31. Østerud B, Unruh D, Olsen J, et al. Procoagulant and proinflammatory effects of red blood cells on lipopolysaccharide-stimulated monocytes. *Journal of Thrombosis and Haemostasis*. 2015;13(9):1676-82.
32. Aleman MM, Byrnes JR, Wang J-G, et al. Factor XIII activity mediates red blood cell retention in venous thrombi. *The Journal of clinical investigation*. 2014;124(8):3590-600.
33. Byrnes JR, Duval C, Wang Y, et al. Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin  $\alpha$ -chain crosslinking. *Blood*. 2015;126(16):1940-8.

## FIGURE LEGENDS

**Figure 1: Sequential 3µm sections stained with Martius Scarlet Blue, Anti-CD 42b (Platelets) and Anti-vWF.** (A) MSB staining demonstrating the presence of Red blood cells in Yellow, Fibrin in Red, White blood cells in Blue and Platelets and other in Grey/Pink. (B&C) Immunohistochemical staining with Anti-CD42b for Platelets and Anti-vWF. Sections were stained on a Ventana Discovery Autostainer using a RedMap kit (Red = Positive, Magnification = 0.6x). (D, E&F) Quantification results for each of the respective stains (D) MSD, (E) CD42b and (F) vWF.

**Figure 2: Correlations between clot components.** (A) A significant positive correlation was observed between platelets (CD42b) measured by immunohistochemistry and platelets and other as measured by MSB staining ( $r=0.534^{**}$ ). (B) A significant positive correlation was also observed between platelets (CD42b) and von Willebrand Factor ( $r=0.444^{**}$ ). (C&D) A significant inverse correlation was noted between red blood cells and both: (C) platelets (CD42b) ( $r=-0.535^*$ ) and (D) von Willebrand Factor ( $r=0.366^{**}$ ) (E) A significant positive correlation was observed between platelets (CD42b) and white blood cells ( $r=0.353^{**}$ ). (F) No significant correlation was observed between platelets (CD42b) and Fibrin levels.